Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
- Conditions
- Interventions
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 29
- Registration Number
- NCT01553903
- Locations
- 🇫🇷
Institut Claudius REGAUD, Toulouse, France
Anastrozole in Patients With Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 18
- Registration Number
- NCT01545336
- Locations
- 🇺🇸
University of Pennsylvania - Perelman Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania - Penn Presbyterian, Philadelphia, Pennsylvania, United States
🇺🇸Brown University - Rhode Island Hospital, Providence, Rhode Island, United States
Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 27
- Registration Number
- NCT01520467
- Locations
- 🇫🇷
Explorations Fonctionnelles d'Endocrinologie - Centre de Référence des Maladies Endocriniennes Rares de la Croissance Hôpital Armand Trousseau, Paris, France
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 2
- Registration Number
- NCT01394211
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT01368263
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT01344031
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5018
- Registration Number
- NCT01272037
- Locations
- 🇺🇸
Mills-Peninsula Medical Center, Burlingame, California, United States
🇺🇸Dublin Hematology Oncology Care PC, Dublin, Georgia, United States
🇺🇸Piedmont Fayette Hospital, Fayetteville, Georgia, United States
Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2015-05-21
- Target Recruit Count
- 57
- Registration Number
- NCT01262274
- Locations
- 🇯🇵
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka city, Osaka prefecture, Japan
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 5
- Registration Number
- NCT01234532
- Locations
- 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Joyce Marie Slingerland
- Target Recruit Count
- 71
- Registration Number
- NCT01216176
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Stanford University, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.